Lung Therapeutics, Inc.
- Headquarters
- Austin, TX
- Founded
- 2012
- Latest Form D
- $10.1M, Apr 2022
- Total capital
- $50.4M
- Federal grants
- $1.6M
- 6 awards · 2018–2023
- Private capital raised
- $48.8M
- 5 Form D · last Apr 2022
- 55 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 2
- 24 pending · first 2023
Capital timeline
Latest events
- Federal grantHealth and Human S · Phase I · The Development of CSD peptides for the therapeutic treatment of post-acute sequelae of COVID-19 (PACS)$259K
- Federal grantHealth and Human S · Phase I · The Development of CSD peptides for the therapeutic treatment of post-acute sequelae of COVID-19 (PACS)$259K
- Private capital raisedForm D · SEC · 4th filing$10.1M
- Federal grantHealth and Human S · Phase I · Development And Testing Of Subcutaneous Csd Peptide Formulations For Chronic Kidney Disease$300K
- Federal grantHealth and Human S · Phase I · Development And Testing Of Subcutaneous Csd Peptide Formulations For Chronic Kidney Disease$300K
- Federal grantHealth and Human S · Phase I · Caveolin-1 replacement therapy for the treatment of Idiopathic Pulmonary Fibrosis$225K
- Private capital raisedForm D · SEC · 3rd filing$36.2M
- Private capital raisedForm D · SEC · 2nd filing$1M
- Private capital raisedForm D · SEC · 1st filing$1.6M
Show 1 earlier federal award
- Federal grantHealth and Human S · Phase I · Enhancement of the Beneficial Effects of Mesenchymal Stem Cell (MSC) Treatment by the Caveolin-1 Scaffolding Domain Peptide (CSD)$225K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
1 record has no date or no amount, so it isn’t placed on the timeline.
Founders and team
From SEC Form D filings- Aaron Brian FletcherDirectorNamed in SEC Form D filings
- James Brian WindsorExecutive Officer, DirectorNamed in SEC Form D filings
- Jim Brian MervisDirectorNamed in SEC Form D filings
- Joseph Brian WoelkersDirectorNamed in SEC Form D filings
- Robert Brian MillsDirectorNamed in SEC Form D filings
- R. A. SessionDirectorNamed in SEC Form D filings
Show all 7 people
- Steven Brian IdellDirectorNamed in SEC Form D filings
What it has protected
USPTO · 2 granted of 26- GrantedModified Peptide Fragments Of CAV-1 Protein And The Use Thereof In The Treatment Of FibrosisUSPTOUS 11,905,336
- GrantedModified Peptide Fragments Of CAV-1 Protein And The Use Thereof In The Treatment Of FibrosisUSPTOUS 11,787,838
- PendingCompositions And Methods For Protecting Type 2 Alveolar Epithelial Cells (AEC2)USPTOApplication 17437952
Show all 26 patent records
- Modified Peptide Fragments Of CAV-1 Protein And The Use Thereof In The Treatment Of FibrosisFeb 20, 2024 · US 11,905,336Granted
- Modified Peptide Fragments Of CAV-1 Protein And The Use Thereof In The Treatment Of FibrosisOct 17, 2023 · US 11,787,838Granted
- Compositions And Methods For Protecting Type 2 Alveolar Epithelial Cells (AEC2)May 26, 2022 · Application 17437952Pending
- Modified CAVEOLIN-1 Peptides For The Treatment Of Chronic Kidney DiseaseApplication PCTUS2022078482Pending
- Modified CAVEOLIN-1 Peptide Formulations And Methods Of Manufacturing And Use ThereofApplication 63368169Pending
- Epithelial Sodium Channel (enac) Inhibitor Conjugates And Methods For Use ThereofApplication PCTUS2022073561Pending
- Modified CAVEOLIN-1 Peptides For The Treatment Of Post-acute COVID-19Application PCTUS2022033929Pending
- Biomarkers For The Treatment Of Interstitial Lung DiseaseApplication PCTUS2022017833Pending
- Modified CAVEOLIN-1 Peptides For The Treatment Of Post-acute COVID-19Application 63278258Pending
- Biomarkers For The Treatment Of Interstitial Lung DiseaseApplication 63270867Pending
- Modified CAVEOLIN-1 Peptides For The Treatment Of Chronic Kidney DiseaseApplication 63270852Pending
- Epithelial Sodium Channel (enac) Inhibitor Conjugates And Methods For Use ThereofApplication 63243629Pending
- Epithelial Sodium Channel (enac) Inhibitor Conjugates And Methods For Use ThereofApplication 63219488Pending
- Modified CAVEOLIN-1 Peptides For The Treatment Of Pathogen-induced Lung InjuryApplication PCTUS2021037812Pending
- Modified CAVEOLIN-1 Peptides For The Treatment Of Post-acute COVID-19Application 63211649Pending
- Modified Peptide Fragments Of CAV-1 Protein And Uses ThereofApplication PCTUS2021028326Pending
- Biomarkers For The Treatment Of Interstitial Lung DiseaseApplication 63153565Pending
- Polypeptides For The Treatment Of Pathogen-induced Lung InjuryApplication 63041396Pending
- Modified Peptide Fragments Of CAV-1 Protein And The Use ThereofApplication 63041629Pending
- Modified Peptide Fragments Of CAV-1 Protein And The Use ThereofApplication 63013392Pending
- Compositions And Methods For Protecting Type 2 Alveolar Epithelial Cells (AEC2)Application PCTUS2020021980Pending
- Modified Peptide Fragments Of CAV-1 Protein And The Use Thereof In The Treatment Of FibrosisApplication PCTUS2019050332Pending
- Modified CAVEOLIN-1 Peptide Formulations And Methods Of Manufacturing And Use ThereofApplication 18993188Pending
- Dry Powder Formulation Of CAVEOLIN-1 Peptides And Methods Of Use ThereofApplication PCTUS2019050349Pending
- Modified CAVEOLIN-1 Peptide Formulations And Methods Of Manufacturing And Use ThereofApplication PCTUS2023070053Pending
- Modified CAVEOLIN-1 Peptide Formulations And Methods Of Manufacturing And Use ThereofApplication 63504901Pending
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .